Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome

References

• Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822–1834. doi: 10.1016/j.jacc.2007.07.051
   PubMed Web of Science ®Google Scholar
• Doraiswamy VA, Slepian MJ, Gesheff MG, et al. Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. Expert Rev Cardiovasc Ther. 2013;11(9):1259–1267. doi: 10.1586/14779072.2013.827469
   PubMedGoogle Scholar
• Jeong YH, Tantry US, Gurbel PA. Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opin Pharmacother. 2012;13:1771–96.
   PubMed Web of Science ®Google Scholar
• Tantry US, Navarese EP, Myat A, et al. Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opin Pharmacother. 2018;19(7):653–665. doi: 10.1080/14656566.2018.1457649
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Fox KAA, Tantry US, et al. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation. 2019;139(18):2170–2185. doi: 10.1161/CIRCULATIONAHA.118.033580
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. APPRAISE-2 investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708. doi: 10.1056/NEJMoa1105819
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19. doi: 10.1056/NEJMoa1112277
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in Stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Fredenburgh JC, Weitz JI Factor XI as a Target for New Anticoagulants. Hamostaseologie. 2021;41:104–110. 10.1055/a-1384-3715 02
   PubMed Web of Science ®Google Scholar
• Woodruff RS, Sullenger B, Becker RC The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis. 2011;32:9–20. 10.1007/s11239-011-0578-5 1
   PubMed Web of Science ®Google Scholar
• Mohammed BM, Matafonov A, Ivanov I, et al. An update on factor XI structure and function. Thromb Res. 2018;161:94–105. 10.1016/j.thromres.2017.10.008
   PubMed Web of Science ®Google Scholar
• White-Adams TC, Berny MA, Tucker EI, et al. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol. 2009;29(10):1602–1607. doi: 10.1161/ATVBAHA.109.187393
   PubMed Web of Science ®Google Scholar
• Renné T, Gailani D, Meijers JC, Müller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem. 2002;277:4892–4899
   PubMed Web of Science ®Google Scholar
• Lipets E, Vlasova O, Urnova E, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One. 2014;9(1):e87692. doi: 10.1371/journal.pone.0087692
   PubMed Web of Science ®Google Scholar
• Paszek E, Malinowski KP, Ząbczyk M, et al. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease. Eur J Clin Invest. 2023;53(9):e14007. doi: 10.1111/eci.14007
   PubMed Web of Science ®Google Scholar
• Gailani D, Gruber A. Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36(7):1316–1322. doi: 10.1161/ATVBAHA.116.306925
   PubMed Web of Science ®Google Scholar
• Georgi B, Mielke J, Chaffin M, et al. Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. Stroke. 2019;50(11):3004–3012. doi: 10.1161/STROKEAHA.119.026545
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Bozarth JM, et al. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost. 2022;20(2):399–408. doi: 10.1111/jth.15588
   PubMed Web of Science ®Google Scholar
• Asakai R, Chung DW, Davie EW, et al. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153–158. doi: 10.1056/NEJM199107183250303
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269–273. doi: 10.1160/TH10-05-0307
   PubMed Web of Science ®Google Scholar
• Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210–1215. doi: 10.1182/blood-2016-09-742262
   PubMed Web of Science ®Google Scholar
• Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006;108:4045–4051.
   PubMed Web of Science ®Google Scholar
• Suri MF, Yamagishi K, Aleksic N, et al. Novel hemostatic factor levels and risk of ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Cerebrovasc Dis. 2010;29(5):497–502. doi: 10.1159/000297966
   PubMed Web of Science ®Google Scholar
• Siegerink B, Govers-Riemslag JW, Rosendaal FR, et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the risk of arterial thrombosis in relation to oral contraceptives (RATIO) case-control study. Circulation. 2010;122(18):1854–1861. doi: 10.1161/CIRCULATIONAHA.110.943738
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111(8):4113–4117. doi: 10.1182/blood-2007-10-120139
   PubMed Web of Science ®Google Scholar
• Folsom AR, George KM, Appiah D. Lack of association of plasma factor XI with incident stroke and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2015;243(1):181–185. doi: 10.1016/j.atherosclerosis.2015.09.015
   PubMed Web of Science ®Google Scholar
• Konings J, Govers-Riemslag JW, Spronk HM, et al. Activation of the contact system in patients with a first acute myocardial infarction. Thromb Res. 2013;132:138–42.
   PubMed Web of Science ®Google Scholar
• Tanis B, Algra A, van der Graaf Y, et al. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol. 2006;77(1):67–73. doi: 10.1111/j.1600-0609.2006.00656.x
   PubMed Web of Science ®Google Scholar
• Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113(4):936–944. doi: 10.1182/blood-2008-06-163675
   PubMed Web of Science ®Google Scholar
• Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33(7):1670–1678. doi: 10.1161/ATVBAHA.113.301282
   PubMed Web of Science ®Google Scholar
• Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102–2107. doi: 10.1182/blood-2013-12-540872
   PubMed Web of Science ®Google Scholar
• Ali AE, Becker RC The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease. J Thromb Thrombolysis. 2024 Apr 25. doi: 10.1007/s11239-024-02985-0.
   Web of Science ®Google Scholar
• Dilger AK, Pabbisetty KB, Corte JR, et al. Discovery of Milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. J Med Chem. 2022;65(3):1770–1785. doi: 10.1021/acs.jmedchem.1c00613
   PubMed Web of Science ®Google Scholar
• Wang X, Li Q, Du F, et al.. Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. TH Open. 2023;7(02):e97–e104. doi: 10.1055/a-2061-3311
   PubMedGoogle Scholar
• Perera V, Wang Z, Lubin S, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Sci Rep. 2022;12(1):22239. doi: 10.1038/s41598-022-25936-2
   PubMed Web of Science ®Google Scholar
• Perera V, Wang Z, Lubin S, et al. Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of Milvexian, a factor XIa inhibitor. Cardiol Ther. 2022;11(3):407–419. doi: 10.1007/s40119-022-00266-6
   PubMed Web of Science ®Google Scholar
• Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330–342. doi: 10.1111/cts.13148
   PubMed Web of Science ®Google Scholar
• Perera V, Wang Z, Lubin S, et al. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Sci Rep. 2022;12(1):5165. doi: 10.1038/s41598-022-08768-y
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743–3749. doi: 10.1093/eurheartj/ehaa671
   PubMed Web of Science ®Google Scholar
• Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment. Clin Pharmacokinet. 2022;61(10):1405–1416. doi: 10.1007/s40262-022-01150-1
   PubMed Web of Science ®Google Scholar
• Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G171–6. doi: 10.1152/ajpgi.00402.2017
   PubMed Web of Science ®Google Scholar
• Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of Milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022;61(6):857–867. doi: 10.1007/s40262-022-01110-9
   PubMed Web of Science ®Google Scholar
• Perera V, Abelian G, Luettgen J, et al. A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants Eur Heart J, Volume 43, Issue Supplement-2. 2022 Supplement_2 10.1093/eurheartj/ehac544.2704
   Google Scholar
• Chintala M, Bunce MW, Devine ZH. Lack of interaction of milvexian, an investigational oral FXIa inhibitor with aspirin and ticagrelor on platelet aggregation, thrombin generation and thromboelastography in vitro. PB0558- abstract Presented at ISTH 2023 congress Montreal, Canada.
   Google Scholar
• Weitz JI, Strony J, Ageno W, et al. AXIOMATIC-TKR investigators. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161–2172. doi: 10.1056/NEJMoa2113194
   PubMed Web of Science ®Google Scholar
• Gill D, Georgakis MK, Laffan M, et al. Genetically determined FXI (factor XI) levels and risk of stroke. Stroke. 2018;49(11):2761–2763. doi: 10.1161/STROKEAHA.118.022792
   PubMed Web of Science ®Google Scholar
• Rohmann JL, Huo S, Sperber PS, et al. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. J Thromb Haemost. 2020;18(12):3316–3324. doi: 10.1111/jth.15092
   PubMed Web of Science ®Google Scholar
• Sharma M, Molina CA, Toyoda K, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46–59. doi: 10.1016/S1474-4422(23)00403-9
   PubMed Web of Science ®Google Scholar
• Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation. https://news.bms.com/news/details/2023/Milvexian-Granted-U.S.-FDA-Fast-Track-Designation-for-All-Three-Indications-Under-Evaluation-in-Phase-3-Librexia-Program-Ischemic-Stroke-Acute-Coronary-Syndrome-and-Atrial-Fibrillation/default.aspx. Accessed on 5-21-2024
   Google Scholar
• XARELTO (rivaroxaban) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf. Accessed on 5-13-2024
   Google Scholar
• Xarelto, rivaroxaban. https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto
   Google Scholar
• Wichaiyo S, Parichatikanond W, Visansirikul S, et al. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis. ACS Pharmacol Transl Sci. 2023;6:970–981.
   PubMedGoogle Scholar
• Rao SV, Kirsch B, Bhatt DL, et al. PACIFIC AMI investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196–1206. doi: 10.1161/CIRCULATIONAHA.122.061612
   PubMed Web of Science ®Google Scholar
• OCEANIC-AF study stopped early due to lack of efficacy. https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-ofefficacy. Accessed on 7-10-2024
   Google Scholar